JP2022525148A5 - - Google Patents

Info

Publication number
JP2022525148A5
JP2022525148A5 JP2021555221A JP2021555221A JP2022525148A5 JP 2022525148 A5 JP2022525148 A5 JP 2022525148A5 JP 2021555221 A JP2021555221 A JP 2021555221A JP 2021555221 A JP2021555221 A JP 2021555221A JP 2022525148 A5 JP2022525148 A5 JP 2022525148A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
composition according
cystamine
cysteamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021555221A
Other languages
English (en)
Japanese (ja)
Other versions
JP7538541B2 (ja
JP2022525148A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025067 external-priority patent/WO2020198529A1/en
Publication of JP2022525148A publication Critical patent/JP2022525148A/ja
Publication of JP2022525148A5 publication Critical patent/JP2022525148A5/ja
Application granted granted Critical
Publication of JP7538541B2 publication Critical patent/JP7538541B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021555221A 2019-03-26 2020-03-26 置換されたアミノチオール及びアミノジスルフィド化合物、及びそれらの使用 Active JP7538541B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962823892P 2019-03-26 2019-03-26
US62/823,892 2019-03-26
PCT/US2020/025067 WO2020198529A1 (en) 2019-03-26 2020-03-26 Substituted amino-thiol and amino-disulfide compounds, and uses thereof

Publications (3)

Publication Number Publication Date
JP2022525148A JP2022525148A (ja) 2022-05-11
JP2022525148A5 true JP2022525148A5 (enExample) 2023-03-16
JP7538541B2 JP7538541B2 (ja) 2024-08-22

Family

ID=72610131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021555221A Active JP7538541B2 (ja) 2019-03-26 2020-03-26 置換されたアミノチオール及びアミノジスルフィド化合物、及びそれらの使用

Country Status (5)

Country Link
US (1) US12391643B2 (enExample)
EP (1) EP3946298A4 (enExample)
JP (1) JP7538541B2 (enExample)
CN (1) CN113613642B (enExample)
WO (1) WO2020198529A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021022012A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN115745857B (zh) * 2022-10-28 2025-10-17 中国医学科学院放射医学研究所 一类口服给药的活性氧响应的硫酯类化合物、合成方法及用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254730A (en) * 1992-01-14 1993-10-19 Kilgore James L Production of amino acids and amino acid derivatives bearing isotopic hydrogen labels
PT1919458E (pt) 2006-01-27 2012-08-23 Univ California Cisteamina revestida entericamente, cisteamina e seus derivados
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
HRP20130590T1 (en) 2007-11-30 2013-08-31 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
US8530479B2 (en) * 2009-08-10 2013-09-10 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides
CA2732440C (en) * 2011-02-23 2017-10-31 Universite Laval Cystamine analogues for the treatment of parkinson`s disease
TW201618760A (zh) 2014-11-05 2016-06-01 雷普特製藥有限公司 使用半胱胺組合物治療亨廷頓氏病之方法
CA3017797A1 (en) 2016-03-17 2017-09-21 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
WO2021022012A1 (en) 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases

Similar Documents

Publication Publication Date Title
JP2012503010A5 (enExample)
JP2010507585A5 (enExample)
JP2012524085A5 (enExample)
JP2009511481A5 (enExample)
ES2633658T3 (es) Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
US20240366591A1 (en) Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
JP2009538359A5 (enExample)
JP2009539863A5 (enExample)
US11191757B2 (en) Combination of pimavanserin and cytochrome P450 modulators
KR20160117596A (ko) 신규 제약 제제
JP2022525148A5 (enExample)
JP2010512343A5 (enExample)
US10953000B2 (en) Combination of pimavanserin and cytochrome P450 modulators
JP2016529228A5 (enExample)
US20100247645A1 (en) Pharmaceutical combination of aliskiren and valsartan
CA2631581A1 (en) Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
JP2022529189A (ja) 持続放出製剤
US9550780B2 (en) Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP4278652B2 (ja) 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物
JP2018507210A5 (enExample)
JP2025509969A5 (enExample)
US7741334B2 (en) Low dose therapy for treating viral infections
JP2023507387A5 (enExample)
US20170182024A1 (en) Pharmaceutical composition for the treatment of parkinson's disease
RU2024129873A (ru) Дейтерированные аналоги пиррольных ингибиторов erk, их синтез и промежуточные соединения